α-synuclein fibrils per se but not α-synuclein seeded aggregation causes mitochondrial dysfunction and cell death in human neurons
One of the major histopathological features of Parkinsons's disease - intracellular Lewy bodies - consists of misfolded α-synuclein. This protein can self-assemble, spread through the brain and seed its own aggregation. Aggregated α-synuclein is shown to induce mitochondrial dysfunction that leads to neuronal loss. Using human iPSC-derived SNCA triplication (3xSNCA) and isogenic control (ISO) neurons we studied whether acute exposure to fibrillar α-synuclein, or its seeding properties, induce effects on mitochondrial function and toxicity. Chronic exposure of neurons to fibrillar α-synuclein (up to 3 weeks) induces a gradual increase of endogenous α-synuclein seeding in neurons, with a decrease in the exogenous fibrillar α-synuclein in ISO and 3xSNCA neurons. Application of exogenous fibrillar α-synuclein induced mitochondrial depolarisation, impairment of complex I function, increased ROS production, oxidative stress and cell death. Notably, α-synuclein seeding following weeks of incubation almost completely restored mitochondrial function and redox balance of human neurons. Thus, mitochondrial dysfunction and oxidative stress in human neurons can be induced acutely only by transient exogenous fibrillar α-synuclein, but seeding is irrelevant to long-term mitochondrial dysfunction or toxicity. This study also indicates an acute, transient toxic insult followed by a remarkable period of adaptation and functional recovery, highlighting the resilience of human neurons.
Authors
- Noemí Esteras
- James R. Evans (ORCID: https://orcid.org/0000-0003-2923-281X)
- Andrey Y. Abramov (ORCID: https://orcid.org/0000-0002-7646-7235)
- Marko Kostić (ORCID: https://orcid.org/0000-0002-0392-4976)
- Jochen H.M. Prehn (ORCID: https://orcid.org/0000-0003-3479-7794)
- Ronald Melki (ORCID: https://orcid.org/0000-0003-0000-7096)
- Plamena R. Angelova
- Sonia Gandhi (ORCID: https://orcid.org/0000-0003-4395-2661)
Institutions
- Centre National de la Recherche Scientifique (FR)
- Queen Mary University of London (GB)
- Science Foundation Ireland (IE)
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
- CEA Paris-Saclay - Etablissement de Fontenay-aux-roses (FR)
- Teva Pharmaceuticals (Israel) (IL)
- Direction de la Recherche Fondamentale (FR)
- National Hospital for Neurology and Neurosurgery (GB)
- University College London (GB)
Publication Details
- Journal
- Redox Biology
- Published
- 2025-08-10
- DOI
- https://doi.org/10.1016/j.redox.2025.103817
- Citations
- 2
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- European Federation of Pharmaceutical Industries and Associations
- European Commission
- Ministerio de Ciencia e Innovación
- Agencia Estatal de Investigación